365 related articles for article (PubMed ID: 19123925)
1. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.
Zabouo G; Imbert AM; Jacquemier J; Finetti P; Moreau T; Esterni B; Birnbaum D; Bertucci F; Chabannon C
Breast Cancer Res; 2009; 11(1):R1. PubMed ID: 19123925
[TBL] [Abstract][Full Text] [Related]
2. JAM-A expression positively correlates with poor prognosis in breast cancer patients.
McSherry EA; McGee SF; Jirstrom K; Doyle EM; Brennan DJ; Landberg G; Dervan PA; Hopkins AM; Gallagher WM
Int J Cancer; 2009 Sep; 125(6):1343-51. PubMed ID: 19533747
[TBL] [Abstract][Full Text] [Related]
3. CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition.
Imbert AM; Garulli C; Choquet E; Koubi M; Aurrand-Lions M; Chabannon C
PLoS One; 2012; 7(8):e43752. PubMed ID: 22952755
[TBL] [Abstract][Full Text] [Related]
4. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.
Uchino M; Kojima H; Wada K; Imada M; Onoda F; Satofuka H; Utsugi T; Murakami Y
BMC Cancer; 2010 Aug; 10():414. PubMed ID: 20696077
[TBL] [Abstract][Full Text] [Related]
5. Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.
Horak CE; Lee JH; Elkahloun AG; Boissan M; Dumont S; Maga TK; Arnaud-Dabernat S; Palmieri D; Stetler-Stevenson WG; Lacombe ML; Meltzer PS; Steeg PS
Cancer Res; 2007 Aug; 67(15):7238-46. PubMed ID: 17671192
[TBL] [Abstract][Full Text] [Related]
6. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer.
Zeng Q; Li W; Lu D; Wu Z; Duan H; Luo Y; Feng J; Yang D; Fu L; Yan X
Proc Natl Acad Sci U S A; 2012 Jan; 109(4):1127-32. PubMed ID: 22210108
[TBL] [Abstract][Full Text] [Related]
7. Subtype-specific accumulation of intracellular zinc pools is associated with the malignant phenotype in breast cancer.
Chandler P; Kochupurakkal BS; Alam S; Richardson AL; Soybel DI; Kelleher SL
Mol Cancer; 2016 Jan; 15():2. PubMed ID: 26728511
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells.
Zeng GF; Cai SX; Wu GJ
BMC Cancer; 2011 Mar; 11():113. PubMed ID: 21450088
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.
Cai D; Cao J; Li Z; Zheng X; Yao Y; Li W; Yuan Z
BMC Cancer; 2009 Apr; 9():102. PubMed ID: 19338666
[TBL] [Abstract][Full Text] [Related]
10. Aberrant promoter methylation may be responsible for the control of CD146 (MCAM) gene expression during breast cancer progression.
Dudzik P; Trojan SE; Ostrowska B; Lasota M; Dulińska-Litewka J; Laidler P; Kocemba-Pilarczyk KA
Acta Biochim Pol; 2019 Dec; 66(4):619-625. PubMed ID: 31826047
[TBL] [Abstract][Full Text] [Related]
11. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
Lee YF; Miller LD; Chan XB; Black MA; Pang B; Ong CW; Salto-Tellez M; Liu ET; Desai KV
Breast Cancer Res; 2012 May; 14(3):R85. PubMed ID: 22621393
[TBL] [Abstract][Full Text] [Related]
12. Differential gene expression in breast cancer cell lines and stroma-tumor differences in microdissected breast cancer biopsies revealed by display array analysis.
Mellick AS; Day CJ; Weinstein SR; Griffiths LR; Morrison NA
Int J Cancer; 2002 Jul; 100(2):172-80. PubMed ID: 12115566
[TBL] [Abstract][Full Text] [Related]
13. The expression of stem cell protein Piwil2 and piR-932 in breast cancer.
Zhang H; Ren Y; Xu H; Pang D; Duan C; Liu C
Surg Oncol; 2013 Dec; 22(4):217-23. PubMed ID: 23992744
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression.
Wu GJ; Wu MW; Wang SW; Liu Z; Qu P; Peng Q; Yang H; Varma VA; Sun QC; Petros JA; Lim SD; Amin MB
Gene; 2001 Nov; 279(1):17-31. PubMed ID: 11722842
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines.
Alexopoulou AN; Leao M; Caballero OL; Da Silva L; Reid L; Lakhani SR; Simpson AJ; Marshall JF; Neville AM; Jat PS
Breast Cancer Res; 2010; 12(4):R51. PubMed ID: 20642837
[TBL] [Abstract][Full Text] [Related]
16. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.
Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ
Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413
[TBL] [Abstract][Full Text] [Related]
17. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
18. Methyl-H3K9-binding protein MPP8 mediates E-cadherin gene silencing and promotes tumour cell motility and invasion.
Kokura K; Sun L; Bedford MT; Fang J
EMBO J; 2010 Nov; 29(21):3673-87. PubMed ID: 20871592
[TBL] [Abstract][Full Text] [Related]
19. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.
Zia MK; Rmali KA; Watkins G; Mansel RE; Jiang WG
Int J Mol Med; 2007 Oct; 20(4):605-11. PubMed ID: 17786294
[TBL] [Abstract][Full Text] [Related]
20. TES was epigenetically silenced and suppressed the epithelial-mesenchymal transition in breast cancer.
Yongbin Y; Jinghua L; Zhanxue Z; Aimin Z; Youchao J; Yanhong S; Manjing J
Tumour Biol; 2014 Nov; 35(11):11381-9. PubMed ID: 25119600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
